Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soquelitinib in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS
NCT06730126Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of soquelitinib in autoimmune lymphoproliferative syndrome (ALPS), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Reduction of spleen volume or target lymph node volume by 25% at 90 days. Started Mar 2025; status: recruiting.
02
Drugs
soquelitinib
03
Conditions
autoimmune lymphoproliferative syndrome (ALPS)
Beyond the preview
Go deeper on NCT06730126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730126.